CUSIP: 62921N105
Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
30,436,879
-
Share change
-
+430,646
-
Total reported value
-
$484,291,987
-
Price per share
-
$15.91
-
Number of holders
-
78
-
Value change
-
+$5,934,350
-
Number of buys
-
32
-
Number of sells
-
39
Quarterly Holders Quick Answers
What is CUSIP 62921N105?
CUSIP 62921N105 identifies NGM - NGM BIOPHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2020
-
Previous quarter:
Q2 2020
Recent filing periods for CUSIP 62921N105:
Institutional Holders of NGM BIOPHARMACEUTICALS INC - COM (NGM) as of Q3 2020
As of 30 Sep 2020,
NGM BIOPHARMACEUTICALS INC - COM (NGM) was held by
78 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,436,879 shares.
The largest 10 holders included
Svennilson Peter, BlackRock Inc., Point72 Asset Management, L.P., Greenspring Associates, LLC, VANGUARD GROUP INC, Aquilo Capital Management, LLC, STATE STREET CORP, Rock Springs Capital Management LP, Jasper Ridge Partners, L.P., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
78
institutional shareholders reporting positions in this security
for the Q3 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.